Its most advanced use, the CagriSema combination, has produced late-stage trial data but remains under regulatory review
For companies across the pharmaceutical value chain, the opportunity is not just to follow the shift from injectables to oral delivery
Why advancing is key The goal of oral drug technologies is to beat GLP1s' fragility in the digestive tract, potentially replacing injections for many patients by improving convenience and adherence
[6] Proposed mechanisms for cardiovascular benefits of incretin-based therapies include: Vascular effects : Improved endothelial function and reduced arterial stiffness Anti-inflammatory actions : Decreased systemic inflammation and oxidative stress Metabolic improvements : Enhanced insulin sensitivity and reduced hepatic glucose production Hemodynamic changes : Blood pressure reduction, though with modest increases in heart rate Renal protection : Reduced albuminuria and preservation of kidney function The cardiovascular benefits appear partially independent of weight loss itself, suggesting potential cardioprotective properties of incretin pathway activation
powder : depends on the application The popularity of MCT oil has created quite the market for it within the supplement industry
Hypertension in adults: diagnosis and management (NG136) Recommendations chapter